DURHAM, N.C., Sept. 24 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO - News) today announced that the company has submitted a patent application for a new invention that uses Oxycyte® perfluorocarbon to deliver oxygen as a first aid treatment for victims of heart attacks and strokes. Oxycyte is the Company’s perfluorocarbon (PFC) therapeutic oxygen carrier.
The invention provides an immediate supply of Oxycyte and oxygen to the victim of a heart attack or stroke until medical help is available. It may be easily used by a person who has suffered a heart attack or stroke, but is still conscious, without the assistance of another. It may also be used easily by someone who cannot adequately perform CPR in order to assist someone who is unconscious.
By safely combining Oxycyte and oxygen in a device without pressure, and administering both together with the help of a self-propelled compressor, Oxycyte is able to absorb and carry into the victim’s lungs an oxygen load that is 50 times greater than what the same volume of blood is able to carry. The concept of this invention is to administer oxygen-enriched Oxycyte through the lungs to reach oxygen-deprived tissues even when circulation is obstructed and/or a person has stopped breathing.
“This exciting new invention builds on our other intellectual property and gives us a way to leverage even greater value from our key product, Oxycyte. We’ve already named the invention Vitavent(TM). Ultimately, I see this device being sold over the counter and present wherever there is a defibrillator as well as in any home where there is concern about a potential heart attack or stroke for a loved one,” said Chris Stern, company chairman and CEO. “We are already working on the market prototypes and intend to file a new device application with the FDA as soon as possible.”
“With Vitavent, we now have a fourth pillar for our business strategy. It joins our cosmetic application, Dermacyte(TM), which we intend to launch in Q4; Wundecyte(TM), our wound care device and application; and our clinical compound Oxycyte, which is now in a Phase II-b clinical trial for Traumatic Brain Injury,” said Stern.
About Oxygen Biotherapeutics, Inc.
Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine(TM). The company has under development a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte®) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes wounds and ulcers, and cosmetic applications. More information is available at www.oxybiomed.com.
Caution Regarding Forward-Looking Statements
This news release contains certain forward-looking statements by Oxygen Biotherapeutics, Inc. that involve risks and uncertainties and reflect the company’s judgment as of the date of this release. These statements include those referring to the patent application, uses, market opportunities, and goals for bringing to market a new invention the company calls Vitavent. Actual events or results may differ from Oxygen Biotherapeutics, Inc.'s expectations. There can be no assurance that the U.S. Patent and Trademark Office will grant the patent in a timely manner or at all, that the FDA will approve the product for market, that over-the-counter sales will be permitted, or if permitted that there will be market acceptance of the product at any meaningful level. Additional information concerning these and other risk factors affecting Oxygen Biotherapeutics, Inc.'s business can be found in the company’s public periodic filings with the Securities and Exchange Commission, which are available via www.oxybiomed.com. Oxygen Biotherapeutics, Inc. disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
